LifeStance Health Group, Inc. entered into an underwriting agreement on September 9, 2026, for the offering of 22,250,000 shares of common stock by selling stockholders. The company agreed to purchase 2,000,000 of these shares from the underwriter at the same price paid by the underwriter to the sellers. Barclays Capital Inc. served as the underwriter. The closing occurred on September 11, 2026. LifeStance Health Group did not receive any proceeds from this transaction. The company operates in the healthcare industry, providing mental health and behavioral health services.

LifeStance Health Group reported second quarter 2026 results with revenue of $435.4 million, a 26% increase year-over-year, driven by an 11% growth in its clinician base to 8,542 and a 19% rise in visit volumes to 2.6 million. The company achieved net income of $23.6 million compared to a loss of $3.8 million in the prior year period, while Adjusted EBITDA nearly doubled to $66.0 million. Management raised full-year 2026 revenue guidance to $1.685 billion–$1.725 billion and Center Margin expectations to $570 million–$594 million. Additionally, the Board approved a new $100 million share repurchase program replacing an existing authorization. LifeStance Health Group operates in the healthcare industry as one of the nation's largest providers of outpatient mental healthcare services.

Jeffrey Rhodes resigned from the LifeStance Health Group, Inc. Board of Directors and its committees effective July 2, 2026. To fill the vacancies, the Board appointed Thurman Justice and Lori Goltermann as Class II directors (serving until 2029) and Safwan Shabab as a Class III director (serving until 2027). Thurman Justice and Lori Goltermann received initial restricted stock unit awards of 35,492 units each. LifeStance Health Group, Inc. provides mental health services.